Drug Trial Radar · NCT04647435
Efficacy and Safety of APSCTC for the Treatment of Postsurgical Pain Due to Third Molar Extraction
Last checked: Nov 20, 2026Latest source record: Sep 4, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
396
Actual
Start
May 13, 2023
Primary completion
Oct 4, 2024
Study completion Oct 4, 2024
Sponsor
- Lead sponsor
- Apsen Farmaceutica S.A.Industry
- Sponsor type
- Industry
- First posted
- Dec 1, 2020
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 40 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the efficacy of APSCTC compared to two active drugs in acute pain relief.
Conditions
- Postsurgical Pain
- Third Molar Extraction
Interventions
APSCTCDrug
APSCTC + Toragesic® placebo + Tramal® placebo
Toragesic®Drug
APSCTC placebo + Toragesic® + Tramal® placebo
Tramal®Drug
APSCTC placebo + Toragesic® placebo + Tramal®
Primary outcomes
What the sponsor says the trial is designed to measure.
- At least 50% of maximum pain relief score (TOTPARmax)Time frame: Change from Baseline to 6 hours
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Azidus Brasil Pesquisa Científica e Desenvolvimento Ltda.
Valinhos, São Paulo, Brazil
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.